SCYNEXIS, Inc. (NasdaqCM: SCYX)
Health Care · Pharmaceuticals · US
$5.67
+9.25% today · -23.2% 1Y
SCYNEXIS, Inc. (NasdaqCM: SCYX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $51.64M and employs 18 people.
Over the last twelve months the share price has lost 23.2%, trading between 3.53 and 10.48.
Tweenvest scores SCYNEXIS, Inc. across four factors: quality 47/100, value 60/100. Its strongest factor is value.
SCYX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $51.64M
- Revenue (TTM)
- $19.22M
- P/E
- —
- EPS
- -1.33
- Dividend yield
- —
- Beta (5Y)
- 1.10
- 52-week high
- $10.48
- 52-week low
- $3.53
- Avg volume (3M)
- —
- Shares outstanding
- 9.95M
- Employees
- 18
- Next earnings
- —
About SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
- ISIN
- US8112923094
- Founded
- 1999
- Listed since
- May 2, 2014
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.